详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance

5| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Shanghai Jiao Tong Univ, Rui Jin Hosp, Dept Hematol, Sch Med, 197 Ruijin Er Rd, Shanghai, Peoples R China [2]Shanghai Tongren Hosp, Hongqiao Int Inst Med, Shanghai, Peoples R China [3]Shanghai Jiao Tong Univ, Fac Basic Med, Chem Biol Div Shanghai Univ E Inst,Sch Med, Key Lab Cell Differentiat & Apoptosis,Natl Minist, Shanghai, Peoples R China

出处：

DOI：

ISSN：

关键词： BKM120 bortezomib drug resistance mouse model multiple myeloma cells

摘要：

Proteasome inhibitor bortezomib has proven efficacy against multiple myeloma. However, bortezomib activates the phosphatidylinositol 3-kinase/AKT (PI3K/AKT) pathway (which is essential to the development of myeloma), often resulting in drug resistance and disease recurrence. The addition of BKM120 significantly enhanced the apoptotic effects of bortezomib in both bortezomib-sensitive and bortezomib-resistant cells. Treatment with bortezomib alone increased the phosphorylation of AKT (P-AKT), whereas the addition of BKM120 markedly downregulated P-AKT in both bortezomib-sensitive and bortezomib-resistant cells. The clinical relevance of combined treatment with bortezomib and BKM120 was investigated in a xenograft mouse model and in myeloma patients, and the synergy of the combination was confirmed. In conclusion, the addition of BKM120 enhanced the sensitivity of myeloma cells to bortezomib.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2016]版：

大类 | 3 区医学

小类 | 3 区血液学 3 区肿瘤学

最新[2025]版：

大类 | 4 区医学

小类 | 4 区血液学 4 区肿瘤学

JCR分区：

出版当年[2015]版：

Q2 HEMATOLOGY Q2 ONCOLOGY

最新[2023]版：

Q3 HEMATOLOGY Q3 ONCOLOGY

影响因子： 2.2 最新[2023版] 2.5 最新五年平均 3.093 出版当年[2015版] 2.704 出版当年五年平均 2.891 出版前一年[2014版] 2.755 出版后一年[2016版]

第一作者：

第一作者机构： [1]Shanghai Jiao Tong Univ, Rui Jin Hosp, Dept Hematol, Sch Med, 197 Ruijin Er Rd, Shanghai, Peoples R China

通讯作者：

通讯机构： [1]Shanghai Jiao Tong Univ, Rui Jin Hosp, Dept Hematol, Sch Med, 197 Ruijin Er Rd, Shanghai, Peoples R China [*1]Department of Hematology, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, No. 197, Ruijin Er Road, Shanghai, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]PPP2R5C对多发性骨髓瘤细胞增殖、凋亡和药物敏感性的影响 [2]YL064 directly inhibits STAT3 activity to induce apoptosis of multiple myeloma cells [3]Single-cell RNA sequencing infers the role of malignant cells in drug-resistant multiple myeloma [4]细胞信号转导与肿瘤多药耐药性基因 [5]JaponiconeA induces apoptosis of bortezomib-sensitive and -resistant myeloma cells in vitro and in vivo by targeting IKK beta [6]JaponiconeA induces apoptosis of bortezomib-sensitive and -resistant myeloma cells in vitro and in vivo by targeting IKK beta [7]RNA干扰技术逆转P-糖蛋白介导的肿瘤多药耐药研究 [8]Single-cell RNA-seq reveals the immune escape and drug resistance mechanisms of mantle cell lymphoma [9]Diagnostic efficacy of an optimized nucleotide MALDI-TOF-MS assay for anti-tuberculosis drug resistance detection [10]Pathogens and drug-resistance of hospital-acquired pneumonia in an EICU in Tianjin, China.